Correction: Jalloul et al. Targeted Alpha Therapy: Exploring the Clinical Insights into 225AcAc-PSMA and Its Relevance Compared with 177LuLu-PSMA in Advanced Prostate Cancer Management. Pharmaceuticals 2025, 18, 1215

Key Points

• To explore the clinical insights into targeted alpha therapy using 225Ac-PSMA compared to 177Lu-PSMA for advanced prostate cancer management.
• Comparison of 225Ac-PSMA and 177Lu-PSMA in clinical settings
• Analysis of therapeutic effectiveness and safety profiles
• Review of existing literature and clinical data on prostate cancer treatment.
• Identified differences in effectiveness between 225Ac-PSMA and 177Lu-PSMA
• Revealed potential advantages of targeted alpha therapy for patient outcomes
• Confirmed safety considerations associated with both treatment options.

Abstract